Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th
April 09 2019 - 2:52PM
InvestorsHub NewsWire
Kali-Extracts To Present Cannabis
Treatment R&D For $170 Million In Pharmaceutical Market
Opportunity On April 17th
Dallas, TX -- April 9, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced an online prestation scheduled
next week for Wednesday, April 17th, where management
will provide details on its patented cannabis extract treatments
targeting a $170 million pharmaceutical market opportunity
currently under development. The company
has recently announced ongoing cannabis extract research and
development targeting four specific health issues: Chronic
Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain
Management, and Epilepsy. The market for Type 2 Diabetes is
expected to be a $64 billion market by 2026. The market
for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is
anticipated to reach $83 billion by 2024. The market for
epilepsy treatment is anticipated to reach $9 billion by 2022.
Beyond the
four specific cannabis therapies currently in various stages of
research and development, KALY has a number of additional target
therapies in its research pipeline which will be highlighted in the
April 17tt presentation.
Between
now and the April 17th presentation, KALY plans to
mention several key updates regarding their business operations
separate from the cannabis extract pharmaceutical research and
development business. These announcements will be further
incorporated into the upcoming April 17th
presentation. The announcements and supplementary
presentation material pertains to where KALY is generating
revenue from its patented cannabis extraction process delivering
proprietary extracts for infusion into non-pharmaceutical
commercial products. For instance, KALY recently announced
finalizing it’s all new 25 mg CBD Extract formulation for beverage
infusion. KALY’s patented extraction process already produces
a 10 mg CBD formulation for Puration, Inc.’s (USOTC:
PURA) (“PURA”) leading EVERx CBD Sports Water. Management
plans to include in the presentation updates on how the 25 mg CBD
Extract formulation pertains to KALY and PURA’s contract to produce
a private labeled CBD water for Generex Biotechnology, Corp.
(OTCQB:
GNBT).
KALY is
a health and wellness company set to generate revenue from its
patented cannabis extraction technology through overlapping
go-to-market strategies. In addition to developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024